Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or ...

Biliary Tract Cancer (BTC): KEYTRUDA may be combined with chemotherapy medicines to treat BTC, a cancer that affects the bile ducts or gallbladder. This treatment is for adults when the cancer has ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo. The conversion to ...

(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become effective on January 1 ...

Merck & Co’s checkpoint inhibitor Keytruda can be given half as often ... virtual congress. Giving a 400 mg dose of the PD-1 inhibitor every six weeks, rather than the approved dosing of 200 ...

When topline phase III data was released in November, hinting at the potential of success, Jefferies analyst Akash Tiwari ...

Keytruda SC also showed a safety profile that’s consistent with IV. Grade 3 or above treatment-related adverse events happened in 47% of patients who received the under-the-skin version and ...

How Does Keytruda Work for RCC? Some cancer cells have what are called checkpoint proteins known as PD-L1 on their cell surface. Some immune cells in our bodies called T cells have proteins on ...

KEYNOTE-811 study showed improved progression-free and overall survival with Keytruda combination. Keytruda's recommended dosing is 200 mg every three weeks or 400 mg every six weeks. The safety ...

BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...